304 related articles for article (PubMed ID: 24439009)
1. Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold.
Espaldon R; Kirby KA; Fung KZ; Hoffman RM; Powell AA; Freedland SJ; Walter LC
Urology; 2014 Mar; 83(3):599-605. PubMed ID: 24439009
[TBL] [Abstract][Full Text] [Related]
2. Total, free, and percent free prostate-specific antigen levels among U.S. men, 2001-04.
Lacher DA; Thompson TD; Hughes JP; Saraiya M
Adv Data; 2006 Dec; (379):1-12. PubMed ID: 17348177
[TBL] [Abstract][Full Text] [Related]
3. Understanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratification.
Chinea FM; Lyapichev K; Epstein JI; Kwon D; Smith PT; Pollack A; Cote RJ; Kryvenko ON
Oncotarget; 2017 Mar; 8(13):20802-20812. PubMed ID: 28160549
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.
Etzioni R; Berry KM; Legler JM; Shaw P
Urology; 2002 Feb; 59(2):251-5. PubMed ID: 11834397
[TBL] [Abstract][Full Text] [Related]
5. Statin medications are associated with a lower probability of having an abnormal screening prostate-specific antigen result.
Shi Y; Fung KZ; Freedland SJ; Hoffman RM; Tang VL; Walter LC
Urology; 2014 Nov; 84(5):1058-65. PubMed ID: 25443902
[TBL] [Abstract][Full Text] [Related]
6. Five-year downstream outcomes following prostate-specific antigen screening in older men.
Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
[TBL] [Abstract][Full Text] [Related]
7. The Relationship of Baseline Prostate Specific Antigen and Risk of Future Prostate Cancer and Its Variance by Race.
Verges DP; Dani H; Sterling WA; Weedon J; Atallah W; Mehta K; Schreiber D; Weiss JP; Karanikolas NT
J Natl Med Assoc; 2017 Spring; 109(1):49-54. PubMed ID: 28259216
[TBL] [Abstract][Full Text] [Related]
8. Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System.
Sutton SS; Crawford ED; Moul JW; Hardin JW; Kruep E
World J Urol; 2016 Aug; 34(8):1107-13. PubMed ID: 26753559
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
[TBL] [Abstract][Full Text] [Related]
10. Elevated prostate-specific antigen levels in black men and white men.
Sawyer R; Berman JJ; Borkowski A; Moore GW
Mod Pathol; 1996 Nov; 9(11):1029-32. PubMed ID: 8933511
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the predictive accuracy of serum prostate specific antigen levels and prostate specific antigen density in the detection of prostate cancer in Hispanic-American and white men.
Lam JS; Cheung YK; Benson MC; Goluboff ET
J Urol; 2003 Aug; 170(2 Pt 1):451-6. PubMed ID: 12853797
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer.
Henderson RJ; Eastham JA; Culkin DJ; Kattan MW; Whatley T; Mata J; Venable D; Sartor O
J Natl Cancer Inst; 1997 Jan; 89(2):134-8. PubMed ID: 8998182
[TBL] [Abstract][Full Text] [Related]
13. Race/ethnicity, risk perception, and receipt of prostate-specific antigen testing.
Shavers VL; Underwood W; Moser RP
J Natl Med Assoc; 2009 Jul; 101(7):698-704. PubMed ID: 19634591
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen concentration in young men: new estimates and review of the literature.
Sutcliffe S; Pakpahan R; Sokoll LJ; Elliott DJ; Nevin RL; Cersovsky SB; Walsh PC; Platz EA
BJU Int; 2012 Dec; 110(11):1627-35. PubMed ID: 22502603
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen testing among young men: an opportunity to improve value.
Lange SM; Ambrose JP; Flynn MC; Lowrance WT; Hanson HA; O'Neil BB
Cancer Med; 2021 Mar; 10(6):2075-2079. PubMed ID: 33626214
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen remains an independent predictor of cancer at prostate biopsy in black american men but not in white men: results from a consecutive series of 914 men.
Latchamsetty KC; Kim J; Porter CR
J Urol; 2006 Mar; 175(3 Pt 1):913-7; discussion 917. PubMed ID: 16469578
[TBL] [Abstract][Full Text] [Related]
17. Should the age specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years?
Powell IJ; Banerjee M; Novallo M; Sakr W; Grignon D; Wood DP; Pontes JE
J Urol; 2000 Jan; 163(1):146-8; discussion 148-9. PubMed ID: 10604333
[TBL] [Abstract][Full Text] [Related]
18. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men.
Smith DS; Carvalhal GF; Mager DE; Bullock AD; Catalona WJ
J Urol; 1998 Nov; 160(5):1734-8. PubMed ID: 9783942
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer detection in Black and White men with abnormal digital rectal examination and prostate specific antigen less then 4 ng./ml.
Fowler JE JR; Bigler SA; Farabaugh PB; Wilson SS
J Urol; 2000 Dec; 164(6):1961-3. PubMed ID: 11061891
[TBL] [Abstract][Full Text] [Related]
20. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
